Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov | Simon G. Coetzee | A. Whittemore | L. Kiemeney | M. Pike | M. Beckmann | P. Fasching | R. Nussbaum | R. Vierkant | T. Sellers | V. Pankratz | A. Hein | F. Couch | J. Chang-Claude | H. Noushmehr | B. Fridley | E. Goode | B. Bonanni | O. Olopade | T. Rebbeck | B. Karlan | J. Benítez | N. Le | A. Berchuck | E. Iversen | G. Giles | T. Dörk | M. Southey | D. Easton | G. Rennert | Xifeng Wu | Qiyuan Li | D. Lambrechts | M. Greene | K. Offit | A. Antoniou | A. Brooks-Wilson | D. Levine | S. Buys | Ya-Yu Tsai | L. Wilkens | P. Hillemanns | X. Shu | Yu-tang Gao | W. Zheng | A. Ziogas | H. Anton-Culver | R. Glasspool | U. Menon | A. Gentry-Maharaj | K. Aben | R. Barkardottir | D. Eccles | G. Chenevix-Trench | L. Brinton | J. Lissowska | H. Nevanlinna | N. Bogdanova | U. Hamann | J. Beesley | C. Lázaro | K. Nathanson | S. Orsulic | J. Cunningham | M. Goodman | S. Kjaer | J. Garber | J. Dennis | E. Dicks | Andrew Lee | K. Aittomäki | A. Meindl | R. Schmutzler | Xianshu Wang | A. Rudolph | I. Andrulis | G. Glendon | A. Mulligan | A. Ekici | P. Radice | P. Peterlongo | S. Manoukian | A. Jakubowska | J. Lubiński | N. Antonenkova | A. Toland | F. Fostira | K. Matsuo | A. Wu | S. Teo | J. Simard | P. Pharoah | J. Tyrer | S. Neuhausen | C. Sutter | U. Eilber | S. Wang-gohrke | J. Vijai | A. Monteiro | S. Gayther | J. Kirk | L. McGuffog | D. Cramer | A. Godwin | P. Concannon | J. Brunet | E. Friedman | N. Tung | E. Imyanitov | N. Wentzensen | B. Rosen | I. Vergote | A. Osorio | R. Ness | Hui-Yi Lin | S. Tognazzo | S. Tchatchou | S. Domchek | D. Stoppa-Lyonnet | N. Lindor | S. Olson | H. Risch | A. Viel | J. Oosterwijk | P. Ganschow | D. Frost | O. Sinilnikova | S. Mazoyer | F. Hogervorst | C. Engel | C. Singer | C. Szabo | K. Claes | L. Kelemen | S. Narod | R. Platte | U. Jensen | Howard C. Shen | K. Odunsi | F. Damiola | I. Campbell | L. Ottini | M. Stenmark-Askmalm | I. Runnebaum | O. Díez | I. Orlow | R. Weber | J. Doherty | J. Schildkraut | K. Moysich | F. Modugno | B. Ji | C. Aghajanian | T. Hansen | K. Lu | M. Bisogna | A. Gerdes | J. McLaughlin | H. Salvesen | L. Massuger | L. Sucheston | B. Arver | Y. Woo | A. V. van Altena | D. Goldgar | K. Kuchenbaecker | E. Bandera | J. Zidan | M. Hildebrandt | C. Pearce | F. Heitz | P. Harter | A. du Bois | M. Thomassen | R. Butzow | K. Lawrenson | Hannah P. Yang | B. Ejlertsen | J. Collée | J. Lester | D. Hazelett | C. Cybulski | M. Teixeira | J. McLaughlin | V. McGuire | A. Bojesen | A. Miron | J. Weitzel | N. Kauff | M. Tischkowitz | J. Rothstein | W. Sieh | M. Terry | C. Walsh | M. Rossing | L. Bernard | B. Peissel | Zhihua Chen | Honglin Song | C. Phelan | A. Jensen | L. Cook | J. Gronwald | M. Rookus | N. Siddiqui | S. Tworoger | T. Kruse | I. Komenaka | J. Kelley | M. Plante | R. Edwards | E. Oláh | E. Høgdall | C. Høgdall | P. Soucy | D. Barrowdale | S. Healey | M. Piedmonte | T. V. Hansen | I. Blanco | M. Montagna | T. Caldés | E. J. van Rensburg | S. Ramus | M. Caligo | R. Janavicius | S. Ellis | L. Papi | Z. Einbeigi | G. Rodriguez | G. Pfeiler | M. Tea | Y. Laitman | L. Jønson | Y. Ding | M. Pujana | P. Mai | M. de la Hoya | C. M. Dorfling | L. Tihomirova | L. Bjørge | C. Krakstad | Y. Lin | J. Permuth-Wey | P. Harrington | I. Konstantopoulou | J. Paul | T. Pejović | I. Rzepecka | A. Dansonka-Mieszkowska | J. Kupryjańczyk | P. Fasching | L. Pelttari | K. Wicklund | P. Thompson | Ann Chen | F. Bruinsma | Yukie T. Bean | K. Carty | M. Dürst | S. Hosono | S. Lambrechts | Alice W. Lee | S. Lele | A. Leminen | Dong Liang | L. Lundvall | E. Poole | I. Schwaab | Y. Shvetsov | K. Terry | I. L. Tangen | H. Hasmad | Janet M. Lee | T. Spindler | M. J. García | Jo Perkins | K. De Leeneer | D. O’Malley | Claudine Isaccs | G. Sukiennicki | A. Berger | M. Soller | A. Liljegren | E. Van Nieuwenhuysen | M. Azmi | Melissa Kellar | L. Nedergaard | Helen Baker | I. McNeish | G. Coetzee | A. Timorek | Matt Freedman | Liisa M. Pelttari | Yvonne G Lin | L. Massuger | A. Lee | Yu-Tang Gao | K. de Leeneer | Ya‐Yu Tsai | T. Pejovic | Andrew J. Lee | Paul D. P. Pharoah | M. Beckmann | M. García | K. Lu | R. P. Weber | A. Monteiro | Frans B. L. Hogervorst | J. Permuth‐Wey | Jennifer Permuth‐Wey | Radka Platte | Steve Ellis | Yu-Tang Gao | Maria Bisogna | E. Friedman | K. Lu | M. Teixeira | J. Paul | A. van Altena | R. Edwards

[1]  B. Stranger,et al.  Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. , 2014, Human molecular genetics.

[2]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[3]  D. Easton,et al.  Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants , 2013, Journal of Medical Genetics.

[4]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[5]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[6]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[7]  Brooke L. Fridley,et al.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.

[8]  A. Whittemore,et al.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 , 2013, Nature Communications.

[9]  W. Chung,et al.  Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk , 2013, PLoS genetics.

[10]  D. Altshuler,et al.  Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk , 2013, PLoS genetics.

[11]  P. Viganò,et al.  An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis , 2012, Journal of Medical Genetics.

[12]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[13]  R. Vierkant,et al.  ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium , 2012, Cancer Causes & Control.

[14]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[15]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[16]  C. Chakraborty,et al.  Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells , 2012, Journal of cellular physiology.

[17]  D. Easton,et al.  Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of High‐Risk Mutations , 2012, Genetic epidemiology.

[18]  A. Berchuck,et al.  Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC) , 2012, Journal of internal medicine.

[19]  J. S. Hoffman,et al.  Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers , 2012, Human mutation.

[20]  W. Chung,et al.  Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[21]  O. Delaneau,et al.  A linear complexity phasing method for thousands of genomes , 2011, Nature Methods.

[22]  C. Shriver,et al.  Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study , 2012, BMC Medical Genetics.

[23]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Nancy F. Hansen,et al.  Predisposition to Cancer Caused by Genetic and Functional Defects of Mammalian Atad5 , 2011, PLoS genetics.

[25]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[26]  R. Drapkin,et al.  Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells , 2011, Journal of visualized experiments : JoVE.

[27]  R. Vierkant,et al.  LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. , 2011, Cancer research.

[28]  D. Gerrelli,et al.  Human RSPO1/R-spondin1 Is Expressed during Early Ovary Development and Augments β-Catenin Signaling , 2011, PloS one.

[29]  Summer S. Han,et al.  Inference from a multiplicative model of joint genetic effects for [corrected] ovarian cancer risk. , 2011, Journal of the National Cancer Institute.

[30]  F. Couch,et al.  Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. , 2011, Journal of the National Cancer Institute.

[31]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[32]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[33]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[34]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[35]  D. Easton,et al.  Evaluating the power to discriminate between highly correlated SNPs in genetic association studies , 2010, Genetic epidemiology.

[36]  I. Jacobs,et al.  Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. , 2010, Neoplasia.

[37]  A. D’Andrea,et al.  Human ELG1 Regulates the Level of Ubiquitinated Proliferating Cell Nuclear Antigen (PCNA) through Its Interactions with PCNA and USP1* , 2010, The Journal of Biological Chemistry.

[38]  A. Dutra,et al.  DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity , 2009, Cell cycle.

[39]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[40]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[41]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[42]  P. Møller,et al.  High Risk for Ovarian Cancer in a Prospective Series Is Restricted to BRCA1/2 Mutation Carriers , 2008, Clinical Cancer Research.

[43]  J. Vandekerckhove,et al.  Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. , 2008, Biochemical and biophysical research communications.

[44]  K. Tomizuka,et al.  R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. , 2008, Human molecular genetics.

[45]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[46]  Joaquín Dopazo,et al.  Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeffect and PupaSuite databases , 2007, Nucleic Acids Res..

[47]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[48]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[49]  E. Dellambra,et al.  R-spondin1 is essential in sex determination, skin differentiation and malignancy , 2006, Nature Genetics.

[50]  Yan Ping Yu,et al.  Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. , 2006, Cancer research.

[51]  Joaquín Dopazo,et al.  PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes , 2006, Nucleic Acids Res..

[52]  L. Bourguignon,et al.  Hyaluronan-CD44 Interaction with IQGAP1 Promotes Cdc42 and ERK Signaling, Leading to Actin Binding, Elk-1/Estrogen Receptor Transcriptional Activation, and Ovarian Cancer Progression* , 2005, Journal of Biological Chemistry.

[53]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[54]  I. Jacobs,et al.  A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro , 2004, Laboratory Investigation.

[55]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[56]  D. Landsittel,et al.  Expression of myopodin induces suppression of tumor growth and metastasis. , 2003, The American journal of pathology.

[57]  C. Cordon-Cardo,et al.  Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome , 2003, Oncogene.

[58]  I. Jacobs,et al.  Histopathologic Features of Genetically Determined Ovarian Cancer , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[59]  M. Becich,et al.  Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. , 2001, The American journal of pathology.

[60]  D. Easton,et al.  A systematic review and meta‐analysis of family history and risk of ovarian cancer , 1998, British journal of obstetrics and gynaecology.

[61]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[62]  R. Sankila,et al.  Cancer incidence in the first-degree relatives of ovarian cancer patients. , 1996, British Journal of Cancer.